NeuraLight’s Post

We were recently interviewed by the Business Post about our vision for Head Diagnostics. Ultimately we believe we can help democratise neurology by developing new digital technologies and an associated neuro platform that is valid, reliable, applicable and practical for neuro healthcare, helping patients and clinicians with better experiences and outcomes. #neurology #digitalmedicine #neuromonitoring #neurotech #neuromodulation #deepbrainstimulation #digitalhealthcare #digitalhealth

Alhamdulillah! 🙌 I am thrilled to share that my latest article, "Optimizing Brain Tumor Classification through Feature Selection and Hyperparameter Tuning in Machine Learning Models," has been published in the prestigious "Informatics in Medicine Unlocked" 📚 a Q2 Open Access journal with a Cite Score of 8 and H-Index of 46. ❤️ I am immensely grateful for the collaboration and support of my team. This publication wouldn't have been possible without the collective effort and dedication towards advancing research in healthcare. Article link: https://lnkd.in/dWwAtxEb #elsevier #medicalinformatics #braintumorclassification #machinelearning #healthcare #bioinformatics

#Congratulations to the ARTORG startup @RetinAI, now rebranded as @Ikerian for closing a very successful Series A Extension with new investors, allowing the young AI and data company to expand operations beyond data management and biomarker detection for eye diseases into new clinical fields, such as neurodegeneration, vascular conditions and rare diseases.   In a media release today, Chief Scientific Officer @Sandro De Zanet was confident that the company’s broader clinical scope will “accelerat(e) clinical studies and enrich AI-based data analysis to support future treatments.” Adding generative AI technology to its established AI platform, Ikerian will facilitate medical imaging analysis across various datasets and support clinical trials. Today's media release in full: https://lnkd.in/gxW54UEu   #Aiinhealthcare #data #management #biomarker #detection #medicalimaging #analysis #clinicalstudies #eyecare #chronicdiseases Innovation Office University of Bern University of Bern Carlos Ciller Stefanos Apostolopoulos Raphael Sznitman Natasa Jovic, B.Sc., MBA Léa Errog

❇❇❇❇❇ INTRODUCING THE CLINICAL SPOTLIGHT SERIES ❇❇❇❇❇ Everyday I chat with clinicians who tell me how much of a game changer using the Vitract gut test has been for their practise. As a practitioner in the integrative care space, you know very well that root caused based thinking is your superpower. It's virtually impossible to treat a chronic illness without thinking about its interaction and relationship with the gut microbiome. However, the gut microbiome is extremely complex! At Vitract, we're extremely lucky to have world renowned experts like Dr. Chidozie Ojobor, Ph.D. on the team leading the development of the gut. With over 10 years of experience in the lab, his grasp on different genomics techniques, how they modulate microbes, the host-pathogen relationship etc is unmatched. We want to every practitioner who uses the Vitract gut test to understand the gut with the same ease. This is why we're building Vitract. We leverage AI coupled with deep domain experts on our R&D team of PhDs to DO THE HARD WORK of making the gut microbiome accessible. If you're a practitioner, patient, or microbiome enthusiast - stay tuned as we'll be sharing something we call the Clinical Spotlight Series. Here, we'll share insights from our team, along with the amazing clinicians who use this test to deliver the best care possible ✨

Dr. Clinton Campbell, a distinguished Hematopathologist at William Osler Health System, is here to unravel the exciting realm of AI-driven computational pathology and its profound implications for diagnostic medicine. 🚀 This illuminating session on "Domain-General vs. Domain-Specific Pre-trained Models: Binary Patch Grouping for Enhanced Whole Slide Image (WSI) Representation" took us on a journey through the intricate process of extracting vital patch features and aggregating them into a meaningful whole. We discovered groundbreaking findings that underscore the pivotal role of BPG across different feature extraction and aggregation methods and gained profound insights into how these slide-level representations are poised to redefine digital pathology, streamline workflows, and unlock new possibilities in healthcare. #PathVisions23

🔬 Finding out what's going on in your cells 🔍Explore the world of cellular storytelling! Understanding disorders starts with understanding each cell's unique story. This is why it matters: - For more effective and targeted healthcare, use personalized medicine. - The ability to analyze cell behavior opens up a window for early detection, allowing proactive measures to be taken. - Discover how cells react to stimuli to develop precise and minimally invasive therapies. - Understand intricate cell interactions to unravel the complexities of disorders. 🔥 Living single-cell analysis is at the forefront of decoding cellular language. Collaborating across disciplines is key to celebrating our cells as storytellers. 🚀 Decode cellular narratives with #SPAchip technology by ARRAYS FOR CELL NANODEVICES, SL - A4CELL to transform healthcare! #CellBiology #HealthcareInnovation #PersonalizedMedicine #ScienceCommunication #CellularAnalysis #MedicalResearch 🧪🔬

How can #digitaltwins transform #healthcare? This question will be discussed at the First International Symposium on Digital Twins in Healthcare with MunichImaging coordinated #OPTOMICS #HorizonEurope project and the projects #DIGIPREDICT, #Neurotwin, and #EDITH_CSA There are several plenary speakers from #Optomics: Vasilis Ntziachristos from MunichImaging, Eleftheria Zeggini at Helmholtz Munich, Anne Demoisy at Rizome s.a. and Ivy Curren from MunichImaging in the panel discussion. Learn more about the symposium held from 16-17. May in Cypress here: https://lnkd.in/djKDZNJ2 Digital Twins are driving a revolution in human model development by leveraging data from multi-#omics analyses, #medical and #imaging data, environmental and life style #bigdata that are continuously updated by a multitude of biosensors at an unprecedented scale. Helmholtz Munich Technical University of Munich European Innovation Council and SMEs Executive Agency (EISMEA)

🌕🎶 Thrilled to be diving into the "Drug Side of the Moon" with you all! 🚀  At Nouscom, we're passionate about sponsoring personalized medicine initiatives that bring us closer to unlocking the mysteries of individualized treatment. Just as Pink Floyd's iconic album took listeners on a journey through unexplored realms, personalized medicine ventures into the uncharted territories of genomic profiling, targeted therapies, and precision medicine. 🧬💊 Imagine a world where treatments are tailored to each patient's unique genetic makeup, where side effects are minimized, and efficacy is maximized. That's the vision we're working towards every day. Through our collaborations and innovations, we're reshaping the landscape of healthcare, bringing us ever closer to a future where every patient receives the right treatment, at the right time, every time. Join us as we venture to the "Drug Side of the Moon" and beyond, transforming the way we approach medicine one personalized therapy at a time. 🌟 #PersonalizedMedicine #PrecisionTherapies #Innovation #Healthcare  #radicalhealth #medicine

“Imaging in general is a very data heavy field … a report for a cardiac computerized tomography (CT) scan used to be half a page and 20 years later it’s six or seven pages, because there’s 20 to 30 quantitative measures that are now used. It’s impossible to keep that up based on manual labor,” he explained. “I remember around six years ago there was a wave of people going around saying your jobs are going to be in danger with AI. I was always thinking that without AI we’re going to be doomed because there’s no way we can actually do the workload.” The use of AI-based medical imaging software for disease diagnostics has increased dramatically in the last few years and continues to become more and more innovative, but it is not the only area in healthcare making use of the potential of AI. The technology is also being used to aid the prediction of disease risk and guide clinicians on whether specific treatments will work for their patients. https://lnkd.in/guNECwNK

LungLife AI (#LLAI) announces the successful validation of its #LungLB® test for indeterminate lung nodules from a prospective, multi-site clinical study in the clinically important small nodules patient group. 🗣 Paul Pagano, #CEO of LungLife AI, said “The key finding from our validation study is LungLB® performed strongly in participants with smaller lung nodules. This is where physicians consistently indicate the greatest unmet need and where currently available tools fall short. This important clinical validation of the LungLB® test is a significant milestone for our Company. While we have identified small nodules as an early commercialisation opportunity, in the background we will continue to optimise the LungLB® test for additional indicated uses, while progressing on the next stage of our programme.” 🔗 Please check here for full announcement, https://lnkd.in/eARJ_eZN